CHARLOTTE, N.C. - Dentsply Sirona Inc. (NASDAQ:XRAY), a global leader in dental products and technologies, has announced the appointment of Michael J. Barber and Daniel T. Scavilla to its Board of Directors, effective Monday. The addition of these executives is part of the company's ongoing board transformation strategy aimed at enhancing its leadership in the evolving dental industry. For detailed analysis of companies in the medical devices sector, InvestingPro offers comprehensive research reports covering over 1,400 US-listed companies.
Michael J. Barber, with a 40-year tenure at General Electric (NYSE:GE), brings extensive experience in product management and innovation, particularly noted for leading GE's digital X-Ray program transformation. He joins the Board's Science and Technology Committee, offering his expertise in diagnostic imaging and point-of-care technology. Barber's current roles include board positions at Exact Sciences, Inc. (NASDAQ:EXAS) and the Green Bay Packers Football Club, among others. According to InvestingPro data, Exact Sciences maintains strong revenue growth of ~12% over the last twelve months, with a healthy gross profit margin of 73%. However, analysts note that profitability remains a key challenge, with the company expected to continue posting losses this year.
Daniel T. Scavilla, currently the CEO of Globus Medical (NYSE:GMED), is recognized for his commercial deployment and business integration acumen, having steered the Globus and NuVasive (NASDAQ:NUVA) merger. Scavilla, who will be part of the Board's Audit and Finance Committee, has a diverse background in finance and operations, with a history of executive roles at Johnson & Johnson.
Greg Lucier, Chairman of the Board at Dentsply Sirona, expressed confidence in the new appointees, stating their combined healthcare experience and technological insight will significantly contribute to the company's mission to transform global dentistry and oral health. For comprehensive analysis of board changes and their potential impact on company performance, investors can access detailed Pro Research Reports available on InvestingPro.
The appointments coincide with the resignation of Dr. Dorothea Wenzel from the Board due to other professional commitments. Lucier thanked Dr. Wenzel for her valuable service and contributions to the company's strategic direction.
With these changes, the Board expands from 10 to 11 members, reflecting Dentsply Sirona's commitment to board diversity and the integration of fresh perspectives to support its strategic goals. The company emphasizes its dedication to driving durable, profitable growth and enhancing shareholder value.
Dentsply Sirona, headquartered in Charlotte, North Carolina, is the world's largest manufacturer of professional dental products and technologies. The company's innovative product portfolio is designed to advance patient care and promote safer and more effective dental care.
This news is based on a press release statement from Dentsply Sirona.
In other recent news, Exact Sciences Corp. has been the focus of several analyst upgrades and new product developments. Barclays (LON:BARC) initiated coverage on Exact Sciences, setting a stock price target of $70 and assigning an Overweight rating. The firm highlighted the company's robust position and potential to meet near-term and long-term targets, despite market concerns over competition for the company's Cologuard test.
Exact Sciences also announced the launch of its Oncodetect MRD test in Q2 2025. The test, which has shown a strong association with recurrence in stage III colon cancer patients, will be available with Medicare coverage. The clinical validation data for the Oncodetect test was presented at the 2025 American Society of Clinical Oncology Gastrointestinal Cancers Symposium.
In addition, CFRA upgraded Exact Sciences from Hold to Buy and raised the price target from $48 to $72. This revised outlook is based on CFRA's analysis that predicts improved sales growth and profitability for Exact Sciences in the coming years. The firm also noted the positive impact of the U.S. Food and Drug Administration's approval of Exact Sciences' Cologuard Plus.
Meanwhile, BTIG raised the price target for Exact Sciences to $75 from $65, maintaining a Buy rating. This followed the news that the company secured approximately $592 per test for Cologuard Plus, marking a 16% increase over the price of the original Cologuard test.
Lastly, TD Cowen increased the stock's price target from $82 to $86, maintaining a Buy rating. This adjustment came after the Centers for Medicare & Medicaid Services set a new pricing benchmark for the company's Cologuard Plus test, which TD Cowen predicts will lead to a 4% rise in revenue and a 10% increase in EBITDA for the year 2028.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.